TipRanks
Matinas BioPharma (DE:6LJ)
FRANKFURT:6LJ
Germany Market
6LJ
Matinas BioPharma
RESEARCH TOOLSreports

Matinas BioPharma (6LJ) Income Statement

0 Followers

Matinas BioPharma Income Statement

Last quarter (Q2 2026), Matinas BioPharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Matinas BioPharma's net income was $-1.33M. See Matinas BioPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 1.10M$ 3.19M$ 33.00K
Gross Profit
$ -456.00K$ -972.00K$ 155.00K$ -13.49M$ -14.55M
Operating Expenses
$ 6.50M$ 19.19M$ 23.92M$ 11.10M$ 10.19M
Depreciation and Amortization
$ 456.00K$ 972.00K$ 941.00K$ 356.00K$ 280.00K
EBITDA
$ -9.89M$ -19.19M$ -22.00M$ -20.64M$ -23.00M
Operating Income
$ -6.96M$ -20.16M$ -23.77M$ -24.59M$ -24.73M
Other Income/Expenses
$ -3.38M$ -4.17M$ 824.00K$ 3.59M$ 1.45M
Pretax Income
$ -10.35M$ -24.33M$ -22.94M$ -21.00M$ -23.28M
Net Income
$ -10.35M$ -24.25M$ -22.94M$ -21.00M$ -23.28M
Per Share Metrics
Basic EPS
$ -30.00$ -74.70$ -79.20$ -45.00$ -75.60
Diluted EPS
$ -30.00$ -74.70$ -79.20$ -45.00$ -75.60
Weighted Average Shares Outstanding
 364.94K 324.39K 289.69K 289.08K 280.24K
Weighted Average Shares Outstanding (Diluted)
 364.94K 324.39K 289.69K 289.08K 280.24K
Currency in USD

Matinas BioPharma Earnings and Revenue History